ADAMCAPITAL Gestao de Recursos Ltda. grew its position in Celgene Co. (NASDAQ:CELG) by 46.6% during the fourth quarter, Holdings Channel reports. The fund owned 568,196 shares of the biopharmaceutical company’s stock after acquiring an additional 180,606 shares during the quarter. Celgene comprises 2.4% of ADAMCAPITAL Gestao de Recursos Ltda.’s investment portfolio, making the stock its 11th biggest position. ADAMCAPITAL Gestao de Recursos Ltda.’s holdings in Celgene were worth $36,416,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in CELG. Buckley Wealth Management LLC increased its position in shares of Celgene by 5.0% during the 4th quarter. Buckley Wealth Management LLC now owns 6,923 shares of the biopharmaceutical company’s stock valued at $444,000 after purchasing an additional 330 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its holdings in Celgene by 29.4% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 8,258 shares of the biopharmaceutical company’s stock valued at $529,000 after acquiring an additional 1,877 shares during the period. Harvey Capital Management Inc. boosted its holdings in Celgene by 9.5% during the 4th quarter. Harvey Capital Management Inc. now owns 81,347 shares of the biopharmaceutical company’s stock valued at $5,213,000 after acquiring an additional 7,067 shares during the period. Blackhill Capital Inc. boosted its holdings in Celgene by 12.9% during the 4th quarter. Blackhill Capital Inc. now owns 28,000 shares of the biopharmaceutical company’s stock valued at $1,795,000 after acquiring an additional 3,200 shares during the period. Finally, Wedge Capital Management L L P NC boosted its holdings in Celgene by 22.2% during the 4th quarter. Wedge Capital Management L L P NC now owns 476,377 shares of the biopharmaceutical company’s stock valued at $30,531,000 after acquiring an additional 86,698 shares during the period. 72.71% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently issued reports on CELG. Mizuho set a $117.00 price objective on Celgene and gave the company a “buy” rating in a report on Tuesday, October 30th. Cantor Fitzgerald restated a “buy” rating and set a $100.00 price objective on shares of Celgene in a report on Thursday, January 3rd. BidaskClub upgraded Celgene from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 5th. JPMorgan Chase & Co. restated a “buy” rating on shares of Celgene in a report on Thursday, October 25th. Finally, Goldman Sachs Group upgraded Celgene from a “sell” rating to a “neutral” rating and boosted their price objective for the company from $71.00 to $88.00 in a report on Thursday, January 3rd. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $109.29.

Shares of CELG stock opened at $87.91 on Friday. Celgene Co. has a twelve month low of $58.59 and a twelve month high of $97.43. The firm has a market capitalization of $60.99 billion, a price-to-earnings ratio of 11.55, a PEG ratio of 0.41 and a beta of 1.72. The company has a debt-to-equity ratio of 4.06, a current ratio of 2.13 and a quick ratio of 1.99.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.32 by $0.07. Celgene had a return on equity of 125.35% and a net margin of 26.48%. The business had revenue of $4.04 billion during the quarter, compared to analysts’ expectations of $3.98 billion. During the same period in the prior year, the business earned $2.00 EPS. As a group, equities analysts forecast that Celgene Co. will post 10.01 EPS for the current year.

WARNING: “ADAMCAPITAL Gestao de Recursos Ltda. Grows Holdings in Celgene Co. (CELG)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2019/02/09/adamcapital-gestao-de-recursos-ltda-grows-holdings-in-celgene-co-celg.html.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: Why do companies engage in swaps?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.